RxDoctor Payments Data

Bradley Green, MD

Family Medicine · Gadsden, ALNPI 1205360666

Payments from drug & device makers

$897in general payments, 2019–2025

Across 15 payments — averaging $59.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$246
  • Biogen$194
  • Pfizer$119
  • Lilly USA, LLC$99
  • GSK$91
  • AbbVie$81
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$246
Biogen2$194
Pfizer1$119
Lilly USA, LLC1$99
GSK1$91
AbbVie2$81
Novo Nordisk1$29
Sanofi1$18
Astellas Pharma US Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$897 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$47,967
Medicare patients
174
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$80,704
JardianceEmpagliflozin24$34,950
FarxigaDapagliflozin Propanediol34$33,237
JanuviaSitagliptin Phosphate13$12,736
Desmopressin Acetate13$2,006
Venlafaxine Hcl ErVenlafaxine Hcl13$1,794
Gabapentin107$1,285
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$1,258
Omeprazole66$1,185
Atorvastatin Calcium102$1,154
Pregabalin28$1,070
Rosuvastatin Calcium36$1,068
Irbesartan24$1,038
Fluticasone Propionate35$862
Albuterol Sulfate HfaAlbuterol Sulfate21$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$80,70461 claims
AstraZenecaFarxiga$246$33,23734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Gadsden

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →